General Organization and Business

9 Months Ended

Jun. 30, 2019

Disclosure Text Block [Abstract]

Nature of Operations [Text Block]

Note 1. General Organization and Business

AngioSoma, Inc., a Nevada corporation (“AngioSoma” or the “Company”), dedicated to improving the mental and physical wellbeing of men and women. To Company created an e-commerce website to market the line of supplements under the SomaCeuticals™ common identity. Supplements cover three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals. 

In addition, the Company is focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease (PAD).

AngioSoma is developing its lead product, a drug candidate called Liprostin^TM for the treatment of peripheral artery disease, or PAD, which has completed FDA Phase I and three Phase II clinical trials. We are in discussions with several contract research organizations for completion of our FDA protocol for Phase III and submission of our new drug application for marketing in the US and its territories.

The Company was incorporated on April 29, 2016. The Company’s year-end is September 30.